ERBB2 and neoplasm: Two tumor grafts (FMT-1701 and FMT-1807) were triple negative basal-like FMT, one tumor graft was luminal A (FMT-1702), another one was HER2-positive (FMT-1806), according to immunohistochemical analysis (Table 1).